Article:Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate. (5457776)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate. and the publication date was 2017-05-08. The initial author is Reza Norouzirad.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Oxidative Medicine and Cellular Longevity

Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate

  • Reza Norouzirad
  • Pedro González-Muniesa
  • Asghar Ghasemi

1Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Dezful University of Medical Sciences, Dezful, Iran

3Centre for Nutrition Research, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain

4Department of Nutrition, Food Sciences and Physiology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain

5IDISNA Navarra's Health Research Institute, Pamplona, Spain

6CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain

Publication date (ppub): /2017

Publication date (epub): 5/2017


The prevalence of obesity and diabetes is increasing worldwide. Obesity and diabetes are associated with oxidative stress, inflammation, endothelial dysfunction, insulin resistance, and glucose intolerance. Obesity, a chronic hypoxic state that is associated with decreased nitric oxide (NO) bioavailability, is one of the main causes of type 2 diabetes. The hypoxia-inducible factor-1α (HIF-1α) is involved in the regulation of several genes of the metabolic pathways including proinflammatory adipokines, endothelial NO synthase (eNOS), and insulin signaling components. It seems that adipose tissue hypoxia and NO-dependent vascular and cellular dysfunctions are responsible for other consequences linked to obesity-related disorders. Although hyperoxia could reverse hypoxic-related disorders, it increases the production of reactive oxygen species (ROS) and decreases the production of NO. Nitrate can restore NO depletion and has antioxidant properties, and recent data support the beneficial effects of nitrate therapy in obesity and diabetes. Although it seems reasonable to combine hyperoxia and nitrate treatments for managing obesity/diabetes, the combined effects have not been investigated yet. This review discusses some aspects of tissue oxygenation and the potential effects of hyperoxia and nitrate interventions on obesity/diabetes management. It can be proposed that concomitant use of hyperoxia and nitrate is justified for managing obesity and diabetes.


1. Introduction

Obesity and diabetes, two major health problems worldwide, have shown an increasing trend in their prevalence over time [[1]]. Obesity, one of the main causes of type 2 diabetes [[2]], is associated with an increased number and size of triglyceride-filled white adipocytes [[3]]. Obesity is a state of hypoxia and low blood flow [[4]]. In this sense, hyperoxia exposure has been evaluated as a treatment for obesity and its related disorders [[5], [6]]. Although hyperoxia has shown beneficial effects for obesity management, it may result in nitric oxide (NO) depletion and induction of oxidative stress [[7][9]]. Interestingly, nitrate, a new proposed therapeutic agent for type 2 diabetes [[10]], restores NO depletion and has antioxidant properties [[11]]. This study reviews the effects of hyperoxia and nitrate interventions on the management of obesity and type 2 diabetes.

2. Adipose Tissue

There are three types of adipocytes or adipose tissues [[12]]. White adipose tissue (WAT) stores energy and lipids, in the form of triglycerides [[3], [12]]. Brown adipose tissue (BAT) dissipates energy and acts as a heat producer; BAT cells produce uncoupling protein 1 (UCP1), which uncouples the respiratory chain, that is, proton transport without phosphorylation, inducing thermogenesis instead of ATP production [[13]]. The third type is the brite or beige adipocytes [[12]]. Beige cells share some characteristics with BAT cells and others with WAT cells [[14]]. cAMP-induced UCP1 expression is higher in beige than in BAT cells; in addition, long-term treatment with thiazolidinedione (TZD) can induce higher UCP1 expression in beige cells than in WAT cells (8- to 10-fold versus 4- to 5-fold) [[15]].

Anatomically, adipose tissues are distributed in central adipose tissues (visceral and upper abdominal subcutaneous fats) and peripheral adipose tissues (hip and gluteofemoral fats) [[16]]. Visceral fat accumulation is associated with oxidative stress and inflammation [[17], [18]]. Adipose tissue is heterogeneous and includes adipocytes, vascular cells, and immune cells [[16]]. This tissue is metabolically active; for example, WAT is an endocrine organ and secretes a large variety of adipokines [[19]]. Table 1 shows some characteristics of different adipocytes.

3. Inflammation of Obese Adipose Tissue and Insulin Resistance

3.1. Obese Adipose Tissue

3.1.1. Adipocyte Death and Turnover

In humans, the turnover of adipocytes is low, that is, ~10% per year, a rate that does not change in the early stages of obesity [[22]]. During the generation of WAT adipocytes, the expression of antiapoptotic factors such as B-cell lymphoma 2 (Bcl2) and flice-inhibitory protein (FLIP) leads to prolonged cell life [[23]]; insulin-like growth factor I (IGF-I) can decrease apoptosis of human fat cells by sustaining the antiapoptotic factors [[24]]. Bcl2 expression is negatively correlated with body mass index and inflammatory cytokines (interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α)) [[25]]. Strissel et al. have reported that adipocyte death in epididymal adipose tissue of C57BL/6 male mice on a high-fat diet is increased from 0.1% at week 1 to 16% at week 12 [[26]]. In addition, the expression of proapoptotic caspases (CASP3, CASP7, CASP8, and CASP9) is increased, while the expression of Bcl2 (an antiapoptotic factor) is decreased in obesity [[25]]. Inflammatory factors such as TNF-α, IL-6, IL-1β, monocyte chemoattractant protein-1 (MCP1), and macrophage recruitment are also increased in obesity; these factors negatively affect adipocyte metabolism and its lipid storage capacity [[2], [25], [27]]. Rammos et al. have shown that 4 weeks of dietary nitrate (sodium nitrate 150 μmol/kg body weight) administration can reduce macrophage migration inflammatory factor (MIF), which is a proinflammatory and atherogenic factor [[28]]. In obesity, BAT cell apoptosis is increased due to the decrease in Bcl2 [[29]] and increase in TNF-α [[30]]; however, low temperature can upregulate the Bcl2 gene expression and may protect BAT against apoptosis in cold situations [[29]].

3.1.2. Lipolysis and Inflammation in Adipocytes

The functions of adipose tissues vary greatly between obese and lean subjects [[25], [31]]. For example, basal lipolysis is higher in obese adipose tissues than in lean ones [[31]]. In addition, elevated levels of fatty acids due to the increased lipolysis, high-fat diets, and hypoxia can result in ectopic fat deposition (as triglycerides and long-chain fatty acid forms) in skeletal muscles, liver, and β-cells; this increased ectopic fat deposition interferes with the normal functions of these tissues; for instance, the high levels of blood fatty acids and TNF-α occurring in obesity can induce insulin resistance [[32][34]]. Furthermore, long-term effects of medium- and long-chain fatty acids on β-cells are K+ channels opening and decrease in insulin secretion [[35]]. By contrast, fatty acids released due to lipolysis in lean subjects bind to coenzyme A to form acyl-CoA, which enters the β-oxidation pathway instead of the circulation, hence reducing the pernicious effects of an excessive free fatty acid release to the blood [[2]]. In inflammatory states, TNF-α, which is induced due to the increase in the numbers of both adipocytes and macrophages, inhibits normal differentiation of preadipocytes and induces proinflammatory phenotypes [[36]]. TNF-α inhibits peroxisome proliferator-activated receptor-γ (PPARγ), which is involved in liver diseases and also lipid metabolism [[37], [38]]. Inhibition of PPARγ increases circulating free fatty acids and therefore intensifies ectopic fat deposition in the liver, skeletal muscles, and other metabolic organs [[2], [37], [38]]. These conditions along with insulin resistance, low insulin production, and/or hyperphagia can worsen the situation and lead to hyperglycemia, glucose intolerance, and eventually diabetes.

3.1.3. Adipose Tissue Macrophages and Inflammation

It has been estimated that the amount of adipose tissue macrophage infiltration in lean mice and humans is under 10% [[39]]. However, this amount is increased up to 50% in extremely obese mice and up to 40% in obese humans [[39]]. Recently, two types of macrophages have been described, based on their activation: M1, classically activated and M2, alternatively activated. A shift from M2 to M1 has been reported in obesity and inflammation [[40]]. Increased TNF-α upregulates MCP1 expression and leads to adipose tissue macrophage infiltration in obesity [[16]]. In addition to MCP1, other chemoattractants are also involved in macrophage recruitment to adipose tissues [[16]]. Some secreted hormones or molecules of adipose tissues are listed in Table 2.

3.2. Insulin Resistance in Obesity

The insulin signaling pathways have been previously reported in detail by several authors [[51], [52]]. As partly shown in Figure 1, phosphorylation of insulin receptor (IR) tyrosine, protein kinase B (PKB), and Akt substrate of 160 kDa (AS160) in insulin signaling pathways is impaired by hypoxia, changes that are reversible by reoxygenation [[53]]; hypoxia also inhibits the insulin-induced phosphorylation of IR substrate 1 (IRS-1) and IRS-2 [[53]]. It has however been shown that the deletion of hepatic prolyl hydroxylase domain enzyme 3 (PHD3) stabilizes the hypoxia-inducible factor-2α (HIF-2α), a key factor of hypoxia responses, and improves insulin sensitivity [[54]] (see Stabilization and Destabilization of HIF-1α). As shown in Figure 1, hypoxia results in increased inflammatory factors and free fatty acids that lead to insulin resistance via the activation of c-Jun amino-terminal kinase 1 (JNK-1) [[55]]. The activation of JNK-1 interferes with insulin signaling via phosphorylation of IRS-1 on serine 307 (Ser307) residue [[56], [57]]. IRS-1 is activated by insulin via tyrosine phosphorylation of IRS-1 in the normal signaling pathway, but the Ser307 phosphorylation of IRS decreases its ability to phosphorylate tyrosine and can therefore cause insulin resistance [[57][59]]. Hirosumi et al. have reported that Ser307 phosphorylation of IRS-1 is increased in wild type obese mice, but not in Jnk1−/− mice [[57]].

Circulating levels of inflammatory factors including free fatty acids and TNF-α are higher in obesity [[55], [57], [60]]; these factors activate JNK-1, resulting in insulin resistance, as aforementioned [[59]]. It should be noted that TNF-α does not directly inhibit IRS-1. The inactivation of JNK-1 in transgenic mice on a high-fat diet leads to increased fatty acid oxidation and energy consumption as well as decreased inflammation [[61]]. In addition, while basal reactive oxygen species (ROS) level has positive effects on both insulin secretion in β-cells and insulin signaling, ROS overproduction is detrimental and can lead to insulin resistance [[62][64]].

3.3. Cellular Stress in Obesity

3.3.1. Mitochondrial Stress

In obesity, the overproduction of ROS leads to adipocyte dysfunction. Increased substrates of the electron transport chain and an increased potential of the mitochondrial inner membrane are the main reasons for increased ROS, in particular the superoxide anion [[65]]. In addition, high glucose level in some cases of obesity can lead to increased ROS signaling [[66]]. The superoxide anion is converted to H2O2 by the enzyme superoxide dismutase; although it is more reactive than H2O2, the latter can pass across the cell membrane, thereby elevating the ROS levels in cytoplasm and affecting macromolecules [[65], [67], [68]]. In BAT and brite cells, ROS increases UCP1, which can lower the potential of mitochondrial membrane and can regulate ROS production [[65], [69]].

3.3.2. Endoplasmic Reticulum Stress

The enlargement of adipocytes leads to increase in protein synthesis, causing endoplasmic reticulum (ER) stress due to inappropriate folding. In addition, chronic high free fatty acid levels can also cause ER stress [[70]]; ER is a site for the synthesis of proteins, sterols, and lipids; if any of these functions are disrupted, it results in ER stress and can cause apoptosis and β-cell death [[70], [71]], which may negatively affect the insulin production.

4. Obese Adipose Tissue Oxygenation

4.1. Hypoxic or Hyperoxic Status of the Adipocytes in Obesity

Oxygenation of adipocytes is different depending on their location and types [[19]]. Ye et al. have reported oxygen pressure (PO2) of epididymal fat in lean and obese mice to be 47.9 and 15.2 mm Hg, respectively, a difference indicating ~70% reduction in the latter [[72]]. Furthermore, it has been reported that hypoxia-induced vascular endothelial growth factor (VEGF) expression is impaired in hyperglycemia/diabetes [[73]]. A 44% decrease in capillary density and 58% in VEGF mRNA in obese compared to lean individuals indicate that low PO2 levels in overweight and obesity do not result in neovascularization [[74]]. In obesity, free fatty acids are increased [[75]], which can induce the uncoupling of oxidation from phosphorylation in mitochondrial respiration via induction of uncoupling proteins such as adenine nucleotide translocase 2 (ANT2); ANT2 subsequently increases oxygen consumption, leading to cell hypoxia [[76]]. There is one report that despite the low blood flow of adipose tissues in obesity, it was suggested that there is an increase in oxygen tension due to low oxygen consumption in mitochondria [[77]]. Different assay methods (O2 electrode versus optochemical measurement) could possibly explain these controversial results. To sum up, several studies have emphasized the hypoxic state of adipose tissues in obesity [[4]].

4.2. Cellular Responses to Hypoxia

Hypoxia can increase cell necrosis and apoptosis in humans and mice. Yin et al. have reported that in vitro hypoxia (1% oxygen for 16 hours) causes 75% cell death in 3T3-L1 adipocytes via increased necrosis (40%) and apoptosis (35%) [[34]]. In obese mice and humans, adipocyte death is correlated with an increase in adipocyte size and macrophage recruitment [[78]]. Hypoxia has a key role in initiating obesity disorders through affecting multiple gene expressions (over 1000 genes) in adipocytes [[79]], in particular HIF-1α [[76]]. Inhibition of ANT2 and/or HIF-1α can reverse the complications of obesity, for example, insulin resistance [[76]]. Furthermore, insulin can induce HIF-1α in 3T3-L1 adipocytes by a ROS-dependent mechanism [[80]]. In addition, ROS (in particular H2O2) can inhibit PHDs, via oxidation of Fe2+ to Fe3+, sustaining thereby the activation of HIF-1α [[81], [82]].

4.2.1. Inflammatory Responses to Hypoxia

Hypoxia affects cellular pathways by stimulation of lipolysis, inhibition of adipogenesis, and adipocyte differentiation [[19], [83]] and consequently increases free fatty acid levels [[19]]; this issue may be due to the downregulation of PPARγ gene expression in a hypoxic state [[83][85]]. Furthermore, hypoxia is correlated with an increased expression of macrophage inflammatory protein-1α (MIP-1α) and macrophage infiltration [[74]]. In obese mice, hypoxia increases expression of inflammatory genes in M1 macrophages, particularly in the adipose tissues [[86]]. Hypoxia induces HIF-1α-dependent and HIF-1α-independent inflammation in visceral but not in subcutaneous fat; this may be due to the presence of M1 macrophages in the former fat and M2 macrophages in the latter fat [[86]].

4.2.2. HIF-1α, a Key Factor for Hypoxia Adaptation in Adipose Tissue

(1) HIF-1α Structure. HIFs are heterodimers of α and β subunits [[87]]. The α subunit contains three isoforms, HIF-1α, HIF-2α, and HIF-3α; HIF-1α and HIF-2α subunits are oxygen sensitive [[88]]. HIF-1α is synthesized in environments with sufficient oxygen levels; however it is targeted for proteasome degradation. The HIF-1β subunit is a shared structural and nonoxygen-sensitive subunit that is required for synthesis of the active form of HIF-1α [[88]]. Both α and β subunits have a Per-ARNT-Sim (PAS) domain, which is involved in HIF-1α heterodimerization and DNA binding [[87], [88]]. The C-terminal side of HIF-1α contains two domains for interaction with the cAMP response element-binding protein- (CREB-) binding protein (CBP) and p300 (CBP/p300) [[87]]. As shown in Figure 2, CBP/p300 recognizes the hypoxia-response element (HRE) in target genes; the products of these genes include cytokines, growth factors, glucose-transporter genes (GLUT1 and GLUT2), and angiogenic genes (VEGF) that are needed for the adaptation to hypoxia [[89], [90]].

(2) Stabilization and Destabilization of HIF-1α. HIF-1α is expressed in all cells, has a half-life of ~1 min, and is regulated via 4-hydroxylation of proline residues (402 or 564) by PHDs, which is oxygen dependent and, in presence of sufficient oxygen, hydroxylates these proline residues [[87]]. Asparagine-803 residue of the α subunit of HIF-1α is hydroxylated by the factor-inhibiting hypoxia-inducible factor (FIH) [[87]]. The 4-hydroxyprolyl HIF-1α binds to the β-domain of von Hippel-Lindau tumor suppressor protein (pVHL) by a hydrogen bond; then pVHL (from its α-domain) binds to Elongin C/B (E3 ligase complex) proteins and induces polyubiquitination of HIF-1α [[91]]. Ubi-HIF-1α is considered a signal for degradation in 26S proteasomes (Figure 3) [[91]]. PHD can hydroxylate the proline residues at several sites of HIF-1α, but only some of them (P402 and P564) react with pVHL and cause 26S degradation; interestingly, the full-length HIF-1α that contains proline to alanine amino acid sequences, P402A/P564A, is resistant to PHD- and pVHL-mediated degradation [[92]].

(3) The Effect of Oxygen and NO on HIF-1α Stabilization. As shown in Figure 3, the activation of PHD requires oxygen, 2-oxoglutarate (2-OG), and binding to Fe+2; this activation is controlled by NO and oxygen levels [[91]]. In hypoxia, mitochondrial consume oxygen and low oxygen levels inactivate PHD; the hydroxylation of the α subunit of HIF-1α is therefore attenuated and binds to the β subunit to produce the active form of HIF-1α [[91]], which is then translocated to the nucleus and binds to CBP/p300; the complex then binds to HRE and other coactivators and controls the transcription of the genes needed for hypoxia adaptation; decreased FIH and production of dehydroxylated asparagine 803 residue are necessary for the binding of HIF-1α and CBP/p300 [[87], [91]]. In addition, hypoxia stimulates inducible NO synthase (iNOS), and NO overproduction inhibits oxygen consumption by mitochondria; this generates a situation similar to normoxia, where oxygen level is not too low to inactivate the PHD and HIF-1α is then degraded in the proteasomes [[93], [94]]; this mechanism may explain the decreases in HIF-1α after the first exposure to hypoxia.

(4) Other Factors That Influence HIF-1α Stabilization. The receptor for activated C kinase 1 (RACK1) competes with heat shock protein 90 (HSP90) to bind to HIF-1α. RACK1 causes polyubiquitination of HIF-1α by binding to Elongin C and ultimately producing Ubi-HIF-1α, which is degraded by proteasomes [[92]]; RACK1-induced degradation of HIF-1α is independent of oxygen, pVHL, and PHD. HSP90 competes with RACK1 to bind to residues 81–200 in the PAS-A subdomain of HIF-1α; the binding of HSP90 to HIF-1α leads to the stabilization of HIF-1α by preventing the binding of RACK1 to HIF-1α [[92]]. Table 3 shows the factors that influence HIF-1α stabilization.

4.2.3. Reciprocal Influences of HIF-1α and Several Cell Pathways and Signals

(1) The Effects of HIF-1α on the Metabolism of Lipids and Carbohydrates. HIF-1α induces glycolysis (glucose fermentation independent of Krebs cycle) in adipocytes both directly by the activation of enolase and 6-phosphofructokinase and indirectly by the activation of 6-phosphofructokinase, fructose-2, 6-biphosphatase, and aldolase C; HIF-1α is also directly involved in the metabolism of lipids (by activation of leptin) and angiogenesis (by induction of VEGF), as well as indirectly disrupting insulin signaling [[96]]. In HIF-1α knockout mice, fed on a high-fat diet, fat mass was decreased, adiponectin induced, and these mice did not develop either obesity or insulin resistance [[97]].

(2) The Effect of HIF-1α on BAT and WAT. HIF-1α may have a dual role in the development of obesity-related disorders, because of its different functions in WAT and BAT cells; Zhang et al. reported that increased HIF-1α induces thermogenesis in BATs by increasing both VEGF-dependent angiogenesis and mitochondria biogenesis; on the other hand, increased HIF-1α increases fibrosis and inflammation in WATs [[98]]. However, it has been reported that the vascular network is diminished in both BAT and WAT in diet-induced obesity; decreased capillary density is higher in BAT than in WAT, leading to BAT whitening; that is, BAT shows the WAT phenotype [[99]]. Interestingly, cold induces VEGF expression independent of hypoxia and HIF-1α in both WAT and BAT cells by PPARγ coactivator 1-α (PGC-1α) [[100]].

Collectively, the overall function of HIF-1α is to adjust cell metabolism on low oxygen consumption. The use of hyperoxia or natural nitrate-containing vegetables may be a strategy to reverse obesity disorders; in support of the nitrate intervention, NO has a positive effect on vascular and capillary tone [[101]] and, unlike BAT whitening factors, causes WAT browning [[102], [103]].

4.2.4. NO Bioavailability in Hypoxia

NO contributes to vasodilation, vascular remodeling, angiogenesis, and glucose metabolism, as well as playing a protective role in cardiovascular disease [[51], [75], [104], [105]]. NO is produced by eNOS via the oxygen-dependent pathway, a route which is disabled in a hypoxic state, where NO would be produced via the nitrate-nitrite-NO pathway, to maintain NO bioavailability [[106]]. Additionally, NO has a very low half-life (~0.05–1.18 ms) [[107]] and acts locally as an autocrine or paracrine factor, whereas nitrite and nitrate act as endocrine hormones and NO reservoirs [[108][110]] due to their longer half-lives (110 s and 5–8 h, respectively) [[107]]. Furthermore, arginine is the common substrate for both arginase and NOS and the increase of arginase activity reduces the arginine needed for NO production by NOS, a status which can cause endothelial dysfunction [[105], [111]]. Interestingly, arginase is upregulated by hypoxia [[111]], TNF-α, and superoxide anion (derived from uncoupled eNOS) [[112]], all occurring in obesity and can act together increasing the susceptibility to diabetes in obese individuals. In vitro hypoxia decreases the phosphorylation of serine-1177 and increases the phosphorylation of threonine-495 in eNOS, reducing its activity; furthermore, hypoxia also decreases arginine transporter [[111], [113], [114]]. In summary, hypoxia decreases NO bioavailability and causes endothelial dysfunction.

4.2.5. NO and Insulin Resistance

Exogenously delivered NO (sodium nitroprusside as a NO donor) stimulates uptake and transendothelial transport (TET) of insulin by inhibition of protein tyrosine phosphatase 1B (PTP1B) via S-nitrosylation; PTP1B dephosphorylates the IRS-1 and IRS-2 tyrosines, as well as inhibiting insulin signaling and TET [[115]]. Insulin resistance increases mitogen-activated protein kinase (MAPK) activity via blocking phosphatidylinositol 3-kinase (PI3K). PI3K increases eNOS activity and NO production, thereby decreasing insulin resistance; in addition, increased MAPK activity leads to vasoconstriction through endothelin-1 [[116]]. Thus, insulin resistance can lead to endothelial dysfunction; reciprocally, endothelial dysfunction can cause insulin resistance [[117]].

Despite previous reports on the carcinogenic effect of dietary nitrate/nitrite [[118], [119]], no association has been found between nitrate/nitrite and the risk of cancer in some later studies [[103], [120], [121]]. Inorganic nitrite increases blood flow of pancreatic islets and stimulates insulin secretion [[122]]. To support the benefits of nitrate intervention, Hezel et al. have demonstrated that long-term dietary nitrate (17 months, NaNO3: 1 mmol/L) improves the response of insulin and concluded that nitrate has no harmful effects on the health of mice [[103]]. As shown in Figure 1, NO and nitrate can also mimic insulin functions and induce GLUT4 translocation to the cell membrane via nitrosylation of GLUT4 [[51]].

Elevated free fatty acids in obesity and hypoxia [[55]] induce inhibitor of kappa B (IκB) kinase β (IKKβ), which phosphorylates serine residues of IRS-1 and interrupts IRS1/PI3k/Akt-dependent eNOS activity that causes NO depletion and impairment of insulin signaling [[123]]. Free fatty acids also interfere with NO production and insulin signaling by other ways including activating Toll-like receptors (TLRs), in particular TLR4, as shown in Figure 1 [[123], [124]].

To summarize, obesity and hypoxia cause oxidative stress and NO depletion, leading to endothelial dysfunction, and consequent obesity disorders. Inorganic nitrate/nitrite apart from replenishing decreased NO bioavailability has antioxidant properties; inorganic nitrite reduces superoxide anion bioavailability and iNOS activity [[11], [125]]. Nitrate administration decreases malondialdehyde (a marker of lipid peroxidation) concentrations and urine concentrations of class VI F2-isoprostanes and 8-hydroxy-2-deoxyguanosine [[126], [127]]. In addition, nitrite can decrease the formation of vascular ROS, perhaps, by the diversion of electrons away from oxygen [[106]].

5. Advantages and Disadvantages of Hyperoxia Intervention

Normobaric and hyperbaric oxygen therapies (NBOT and HBOT, respectively) have been used in medicine. NBOT has beneficial therapeutic effects on severe acute ischemic stroke [[128]], and HBOT is therapeutically used in cardiovascular diseases, sleep apnea, wound healing, and management of some tumors [[129][131]]. Quintero et al. [[5]] were the first to show that hyperoxia (95% O2, 24 h) can increase ROS and proinflammatory adipokines in 3T3-L1 adipocytes; they also showed that hyperoxia upregulates PPARγ that may indirectly have positive effects on insulin sensitivity [[5], [9]]. Treatment with HBOT (2 atmospheres, 2 h/day, 6 times/week, for 5 weeks) increases insulin sensitivity [[132]]. NBOT (60% O2, 3 days) increases adipocyte survival and regeneration in animal models of fat grafting [[133]]. Hyperoxia (35% O2) can reverse the toxic effects of a high-dose glucose (33.3 mM) on INS1 β-cells and restore insulin secretion [[134]]. Chronic moderate hyperoxia (50% O2, for 3 weeks) in male C57BL mice slowed body weight gain and decreased VEGF expression; it however increased HIF-1α level during the first week and decreased it after a prolonged exposure [[95]]. In monosodium glutamate-treated mice, HBOT (2.5 atmospheres, 60 min/d, for 4 weeks with 2 weeks interval) decreased body weight and increased oxidative stress [[7]]. Furthermore, hyperoxia (36% O2 for 3 h daily) in obese type II diabetic rats led to decline in fasting glucose, HbA1c, and the size of adipocytes and increase in metabolic capacity in muscle [[135]]. A review conducted on the effects of HBOT on traumatic brain injury concluded that HBOT has neuroprotective effects via improvement of tissue oxygenation and cellular metabolism and anti-inflammatory and antiapoptotic properties [[136]]; hyperoxia (2.4 atmospheres, 90 min) also decreases inflammation in an animal model of inflammatory pain [[137]]. Hyperoxia depletes 5,6,7,8-tetrahydrobiopterin (BH4) cofactor in the neonatal retina [[8]]. Bioavailability of BH4 is needed for the normal eNOS function, as BH4 depletion can uncouple eNOS, which produces superoxide anion, thereby decreasing NO production [[138]]. Some of the other adverse effects of hyperoxia such as inflammation and oxidative stress have been reported [[7]], as well as anti-inflammatory effects [[136], [137]]. It is interesting to mention that oxidative stress linked to hyperoxia can have a therapeutic action [[139]]. Overall, it seems that hyperoxia has important and undeniable advantages, but its safe dose and exposure duration need to be clearly defined.

6. Conclusions and Perspectives

Obesity is a chronic hypoxic state, which causes several deleterious changes such as adipose tissue dysfunction, insulin resistance, inflammation, and organ damage, changes which can lead to other metabolic disorders including cardiovascular disease and diabetes. In recent years, to prevent the adverse effects of obesity, some interventions have been suggested, such as drugs, exercise, and healthier diet patterns [[140][142]]. Although some researchers indicate that high altitudes and hypoxia can lead to weight loss and lower risk of metabolic syndrome [[143], [144]], these might also have some adverse effects [[145]] such as decrease in muscle mass instead of fat mass, inflammation, macrophages infiltration, and insulin resistance [[146], [147]], indicating that not all individuals can adhere to these conditions. Hyperoxia has beneficial effects and can reverse the aforementioned hypoxic status, for example, insulin sensitivity and wound healing [[146], [148], [149]]. Hyperoxia could be considered as a new strategy for the management of obesity and type 2 diabetes. Exposure to higher doses of oxygen, however, could produce adverse effects [[150][152]] including eNOS inhibition and increased ROS, both of which could contribute to the development of metabolic disorders and adipocyte dysfunction [[153], [154]]. Both acute and chronic exposures to hyperoxia have positive effects on carbohydrate metabolism [[132], [135]], and they can decrease adipocyte size [[7], [135]]. Nonetheless, there are some differences between the types of exposures; for example, acute exposure has anti-inflammatory effects, while chronic exposure has the opposite effects [[5], [9], [137]]. Furthermore, the effects of hyperoxia on oxidative stress and VEGF have been reported in the chronic treatment [[7], [95]]. In addition, there is a report suggesting that hyperoxia during the first week of treatment increased HIF-1α and HIF-2α levels, which were restored to near normal values at 2 to 3 weeks of exposure [[95]]. It has also been shown that hyperoxia inhibits HIF-1α protein expression and DNA-binding activity, in rat INS-1 β cells [[134]]. Further studies are needed to elucidate the acute and chronic effects of hyperoxia.

Recent data support the beneficial effects of a nutritional-based nitrate/nitrite therapy in obesity and diabetes [[108], [155]]. Nitrate has also antioxidant properties [[11]], and it can restore NO depletion induced by hyperoxia. Therefore, for the management of obesity, it seems reasonable to combine hyperoxia and nitrate. To the best of our knowledge, there is no study to address the effect of this combination therapy to manage obesity/diabetes, warranting the need for evaluating the effects of hyperoxia with different durations and oxygen pressures [[7], [156], [157]], viz. on hyperbaric versus normobaric hyperoxia, simultaneously with nitrate intervention.



The authors acknowledge Ms. Niloofar Shiva, an academic faculty member of Research Institute for Endocrine Sciences, for critical editing of the English grammar and syntax of the manuscript. This study has been extracted from a part of the thesis written by Reza Norouzirad, Ph.D. candidate, Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, and was funded and supported by the Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


  1. B. ZhouY. LuK. HajifathalianWorldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participantsLancet2016387100271513153010.1016/S0140-6736(16)00618-82-s2.0-8499441747527061677
  2. A. GuilhermeJ. V. VirbasiusV. PuriM. P. CzechAdipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetesNature Reviews Molecular Cell Biology20089536737710.1038/nrm23912-s2.0-4244909728918401346
  3. R. E. DuncanM. AhmadianK. JaworskiE. Sarkadi-NagyH. S. SulRegulation of lipolysis in adipocytesAnnual Review of Nutrition2007277910110.1146/annurev.nutr.27.061406.0937342-s2.0-3574895480017313320
  4. N. HosogaiA. FukuharaK. OshimaAdipose tissue hypoxia in obesity and its impact on adipocytokine dysregulationDiabetes200756490191110.2337/db06-09112-s2.0-3404711911017395738
  5. P. QuinteroP. Gonzalez-MuniesaD. F. Garcia-DiazJ. A. MartinezEffects of hyperoxia exposure on metabolic markers and gene expression in 3T3-L1 adipocytesJournal of Physiology and Biochemistry201268466366910.1007/s13105-012-0169-82-s2.0-8487132775122535284
  6. P. Gonzalez-MuniesaL. Garcia-GeriqueP. QuinteroS. ArriazaA. Lopez-PascualJ. A. MartinezEffects of hyperoxia on oxygen-related inflammation with a focus on obesityOxidative Medicine and Cellular Longevity20152015p. 11895782710.1155/2016/89578272-s2.0-8494994318626697142
  7. K. TsuneyamaY. C. ChenM. FujimotoAdvantages and disadvantages of hyperbaric oxygen treatment in mice with obesity hyperlipidemia and steatohepatitisThe Scientific World Journal2011112124213510.1100/2011/3802362-s2.0-8145514386222125461
  8. K. S. EdgarN. MatesanzT. A. GardinerZ. S. KatusicD. M. McDonaldHyperoxia depletes (6R)-5,6,7,8-tetrahydrobiopterin levels in the neonatal retina: implications for nitric oxide synthase function in retinopathyThe American Journal of Pathology201518561769178210.1016/j.ajpath.2015.02.0212-s2.0-8492985403625913075
  9. P. QuinteroP. Gonzalez-MuniesaJ. A. MartinezInfluence of different oxygen supply on metabolic markers and gene response in murine adipocytesJournal of Biological Regulators and Homeostatic Agents201226337938823034257
  10. A. GhasemiS. ZahediaslPotential therapeutic effects of nitrate/nitrite and type 2 diabetes mellitusInternational Journal of Endocrinology and Metabolism2013112636410.5812/ijem.91032-s2.0-8487687735523825974
  11. Z. BahadoranA. GhasemiP. MirmiranF. AziziF. HadaeghBeneficial effects of inorganic nitrate/nitrite in type 2 diabetes and its complicationsNutrition & Metabolism2015121p. 1610.1186/s12986-015-0013-62-s2.0-8492930161625991919
  12. S. KeipertM. JastrochBrite/beige fat and UCP1 - is it thermogenesis?Biochimica et Biophysica Acta2014183771075108210.1016/j.bbabio.2014.02.0082-s2.0-8490185085924530356
  13. B. CannonJ. NedergaardBrown adipose tissue: function and physiological significancePhysiological Reviews200484127735910.1152/physrev.00015.20032-s2.0-034798931714715917
  14. V. PeirceS. CarobbioA. Vidal-PuigThe different shades of fatNature20145107503768310.1038/nature134772-s2.0-8490192913324899307
  15. J. WuP. BostromL. M. SparksBeige adipocytes are a distinct type of thermogenic fat cell in mouse and humanCell2012150236637610.1016/j.cell.2012.05.0162-s2.0-8486428750422796012
  16. M. LafontanAdipose tissue and adipocyte dysregulationDiabetes & Metabolism2014401162810.1016/j.diabet.2013.08.0022-s2.0-8489372236224139247
  17. N. AlexopoulosD. KatritsisP. RaggiVisceral adipose tissue as a source of inflammation and promoter of atherosclerosisAtherosclerosis2014233110411210.1016/j.atherosclerosis.2013.12.0232-s2.0-8489382791624529130
  18. K. FujitaH. NishizawaT. FunahashiI. ShimomuraM. ShimabukuroSystemic oxidative stress is associated with visceral fat accumulation and the metabolic syndromeCirculation Journal : Official Journal of the Japanese Circulation Society200670111437144210.1253/circj.70.14372-s2.0-3375056216917062967
  19. P. TrayhurnHypoxia and adipose tissue function and dysfunction in obesityPhysiological Reviews201393112110.1152/physrev.00017.20122-s2.0-8487229019023303904
  20. C. H. SaelyK. GeigerH. DrexelBrown versus white adipose tissue: a mini-reviewGerontology2012581152310.1159/0003213192-s2.0-8415516514421135534
  21. T. B. WaldenI. R. HansenJ. A. TimmonsB. CannonJ. NedergaardRecruited vs. nonrecruited molecular signatures of brown, “brite,” and white adipose tissuesThe American Journal of Physiology - Endocrinology and Metabolism20123021E19E3110.1152/ajpendo.00249.20112-s2.0-8345519839721828341
  22. K. L. SpaldingE. ArnerP. O. WestermarkDynamics of fat cell turnover in humansNature2008453719678378710.1038/nature069022-s2.0-4484913259118454136
  23. S. A. NagelM. KeuperI. ZagottaUp-regulation of Bcl-2 during adipogenesis mediates apoptosis resistance in human adipocytesMolecular and Cellular Endocrinology2014382136837610.1016/j.mce.2013.10.0242-s2.0-8488751257624397922
  24. P. Fischer-PosovszkyH. TornqvistK. M. DebatinM. WabitschInhibition of death-receptor mediated apoptosis in human adipocytes by the insulin-like growth factor I (IGF-I)/IGF-I receptor autocrine circuitEndocrinology200414541849185910.1210/en.2003-09852-s2.0-164246482414691011
  25. F. J. TinahonesL. Coin AraguezM. MurriCaspase induction and BCL2 inhibition in human adipose tissue: a potential relationship with insulin signaling alterationDiabetes Care201336351352110.2337/dc12-01942-s2.0-8487443263923193206
  26. K. J. StrisselZ. StanchevaH. MiyoshiAdipocyte death, adipose tissue remodeling, and obesity complicationsDiabetes200756122910291810.2337/db07-07672-s2.0-3684901205717848624
  27. S. GheibiF. BakhtiarzadehS. JeddiK. FarrokhfallH. ZardoozA. GhasemiNitrite increases glucose-stimulated insulin secretion and islet insulin content in obese type 2 diabetic male ratsNitric Oxide: Biology and Chemistry/Official Journal of the Nitric Oxide Society201764395110.1016/j.niox.2017.01.00328089828
  28. C. RammosU. B. Hendgen-CottaJ. PohlModulation of circulating macrophage migration inhibitory factor in the elderlyBioMed Research International20142014p. 858258610.1155/2014/5825862-s2.0-8490479360325114912
  29. L. BrisciniC. TonelloL. DioniM. O. CarrubaE. NisoliBcl-2 and Bax are involved in the sympathetic protection of brown adipocytes from obesity-linked apoptosisFEBS Letters19984311808410.1016/S0014-5793(98)00730-32-s2.0-003250397700325039779684870
  30. E. NisoliL. BrisciniC. TonelloC. De Giuli-MorghenM. O. CarrubaTumor necrosis factor-alpha induces apoptosis in rat brown adipocytesCell Death and Differentiation19974877177810.1038/sj.cdd.440029216465289
  31. L. HellstromS. ReynisdottirInfluence of heredity for obesity on adipocyte lipolysis in lean and obese subjectsInternational Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity200024334034410.1038/sj.ijo.080113410757628
  32. I. BriaudJ. S. HarmonC. L. KelpeV. B. G. SeguV. PoitoutLipotoxicity of the pancreatic β-cell is associated with glucose-dependent Esterification of fatty acids into neutral lipidsDiabetes200150231532110.2337/diabetes.50.2.315003514578011272142
  33. J. O. EbbertM. D. JensenFat depots, free fatty acids, and dyslipidemiaNutrients20135249850810.3390/nu50204982-s2.0-8487372431123434905
  34. J. YinZ. GaoQ. HeD. ZhouZ. GuoJ. YeRole of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissueAmerican Journal of Physiology Endocrinology and Metabolism20092962E333E34210.1152/ajpendo.90760.20082-s2.0-6084912193719066318
  35. L. BestE. JarmanP. D. BrownA dual action of saturated fatty acids on electrical activity in rat pancreatic beta-cells. Role of volume-regulated anion channel and KATP channel currentsThe Journal of Physiology2011589Part 61307131610.1113/jphysiol.2010.2007412-s2.0-7995261171321242256
  36. P. IsaksonA. HammarstedtB. GustafsonU. SmithImpaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammationDiabetes20095871550155710.2337/db08-17702-s2.0-6765024216419351711
  37. D. VaraC. MorellN. Rodriguez-HencheI. Diaz-LaviadaInvolvement of PPARgamma in the antitumoral action of cannabinoids on hepatocellular carcinomaCell Death & Disease201345, article e61810.1038/cddis.2013.1412-s2.0-8487936258923640460
  38. M. CortezL. S. CarmoM. M. RogeroP. BorelliR. A. FockA high-fat diet increases IL-1, IL-6, and TNF-alpha production by increasing NF-kappaB and attenuating PPAR-gamma expression in bone marrow mesenchymal stem cellsInflammation201336237938610.1007/s10753-012-9557-z2-s2.0-8487949830023079940
  39. S. P. WeisbergD. McCannM. DesaiM. RosenbaumR. L. LeibelA. W. FerranteObesity is associated with macrophage accumulation in adipose tissueThe Journal of Clinical Investigation2003112121796180810.1172/JCI2003192462-s2.0-034823095814679176
  40. C. N. LumengJ. L. BodzinA. R. SaltielObesity induces a phenotypic switch in adipose tissue macrophage polarizationThe Journal of Clinical Investigation2007117117518410.1172/JCI298812-s2.0-3384602671217200717
  41. P. A. KernG. B. Di GregorioT. LuN. RassouliG. RanganathanAdiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expressionDiabetes20035271779178510.2337/diabetes.52.7.1779003767760412829646
  42. Z. V. WangP. E. SchererAdiponectin, the past two decadesJournal of Molecular Cell Biology2016829310010.1093/jmcb/mjw0112-s2.0-8496506086526993047
  43. D. M. SchulteN. MullerK. NeumannPro-inflammatory wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjectsPloS One201272, article e3243710.1371/journal.pone.00324372-s2.0-8485754593422384249
  44. T. EnomotoK. OhashiR. ShibataAdipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolismThe Journal of Biological Chemistry201128640345523455810.1074/jbc.M111.2773192-s2.0-8005341311321849507
  45. D. K. LeeS. R. GeorgeB. F. O'DowdUnravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesityTrends in Pharmacological Sciences200627419019410.1016/
  46. M. V. HeinonenA. K. PurhonenP. MiettinenApelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric bandingRegulatory Peptides20051301-271310.1016/j.regpep.2005.05.0032-s2.0-2204445385215970339
  47. M. SawaneK. KajiyaH. KidoyaM. TakagiF. MuramatsuN. TakakuraApelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrityDiabetes20136261970198010.2337/db12-06042-s2.0-8487825906423378608
  48. R. M. EvansG. D. BarishY. X. WangPPARs and the complex journey to obesityNature Medicine200410435536110.1038/nm10252-s2.0-194251884015057233
  49. A. Jamroz-WisniewskaA. GertlerG. SolomonM. E. WoodM. WhitemanJ. BeltowskiLeptin-induced endothelium-dependent vasorelaxation of peripheral arteries in lean and obese rats: role of nitric oxide and hydrogen sulfidePloS One201491, article e8674410.1371/journal.pone.00867442-s2.0-8489984495024475175
  50. C. M. SteppanS. T. BaileyS. BhatThe hormone resistin links obesity to diabetesNature2001409681830731210.1038/350530002-s2.0-003590575811201732
  51. H. JiangA. C. TorregrossaA. PottsDietary nitrite improves insulin signaling through GLUT4 translocationFree Radical Biology & Medicine201467515710.1016/j.freeradbiomed.2013.10.8092-s2.0-8488811336024157451
  52. M. F. WhiteInsulin signaling in health and diseaseScience200330256511710171110.1126/science.10929522-s2.0-034430578214657487
  53. C. RegazzettiP. PeraldiT. GremeauxHypoxia decreases insulin signaling pathways in adipocytesDiabetes20095819510310.2337/db08-04572-s2.0-6324909355618984735
  54. C. M. TaniguchiE. C. FingerA. J. KriegCross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetesNature Medicine201319101325133010.1038/nm.32942-s2.0-8488747398924037093
  55. A. PriyankaG. SindhuG. L. ShyniM. R. Preetha RaniV. M. NishaK. G. RaghuBilobalide abates inflammation, insulin resistance and secretion of angiogenic factors induced by hypoxia in 3T3-L1 adipocytes by controlling NF-kappaB and JNK activationInternational Immunopharmacology20174220921710.1016/j.intimp.2016.11.01927936435
  56. L. Simon-SzaboM. KokasJ. MandlG. KeriM. CsalaMetformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cellsPloS One201496, article e9786810.1371/journal.pone.00978682-s2.0-8490243623024896641
  57. J. HirosumiG. TuncmanL. ChangA central role for JNK in obesity and insulin resistanceNature2002420691333333610.1038/nature011372-s2.0-003715315812447443
  58. S. T. FerreiraJ. R. ClarkeT. R. BomfimF. G. De FeliceInflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's diseaseAlzheimer's & Dementia : The Journal of the Alzheimer's Association2014101 SupplementS76S8310.1016/j.jalz.2013.12.0102-s2.0-8489788674924529528
  59. X. MaF. FangM. SongS. MaThe effect of isoliquiritigenin on learning and memory impairments induced by high-fat diet via inhibiting TNF-alpha/JNK/IRS signalingBiochemical and Biophysical Research Communications201546441090109510.1016/j.bbrc.2015.07.0812-s2.0-8494045948726188513
  60. N. OuchiK. OhashiR. ShibataT. MuroharaAdipocytokines and obesity-linked disordersNagoya Journal of Medical Science2012741-2193022515108
  61. X. ZhangA. XuS. K. ChungSelective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in miceDiabetes201160248649510.2337/db10-06502-s2.0-7955160085521270260
  62. C. LeloupC. Tourrel-CuzinC. MagnanMitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretionDiabetes200958367368110.2337/db07-10562-s2.0-6274910386819073765
  63. K. LohH. DengA. FukushimaReactive oxygen species enhance insulin sensitivityCell Metabolism200910426027210.1016/j.cmet.2009.08.0092-s2.0-7034951225919808019
  64. S. Di MeoS. IossaP. VendittiSkeletal muscle insulin resistance: role of mitochondria and other ROS sourcesJournal of Endocrinology20172331R15R4210.1530/joe-16-059828232636
  65. F. McMurrayD. A. PattenM. E. HarperReactive oxygen species and oxidative stress in obesity-recent findings and empirical approachesObesity201624112301231010.1002/oby.216542-s2.0-8499398404027804267
  66. T. YuJ. L. RobothamY. YoonIncreased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphologyProceedings of the National Academy of Sciences of the United States of America200610382653265810.1073/pnas.05111541032-s2.0-3364455241716477035
  67. A. BoverisL. B. ValdezT. ZaobornyjJ. BustamanteMitochondrial metabolic states regulate nitric oxide and hydrogen peroxide diffusion to the cytosolBiochimica et Biophysica Acta200617575-653554210.1016/j.bbabio.2006.02.0102-s2.0-3374560922816615992
  68. G. P. BienertJ. K. SchjoerringT. P. JahnMembrane transport of hydrogen peroxideBiochimica et Biophysica Acta200617588994100310.1016/j.bbamem.2006.02.0152-s2.0-3374856498616566894
  69. E. T. ChouchaniL. KazakM. P. JedrychowskiMitochondrial ROS regulate thermogenic energy expenditure and sulfenylation of UCP1Nature2016532759711211610.1038/nature173992-s2.0-8496362544927027295
  70. T. J. BidenE. BoslemK. Y. ChuN. SueLipotoxic endoplasmic reticulum stress, β cell failure, and type 2 diabetes mellitusTrends in Endocrinology & Metabolism2014258389398
  71. I. TabasD. RonIntegrating the mechanisms of apoptosis induced by endoplasmic reticulum stressNature Cell Biology201113318419010.1038/ncb0311-1842-s2.0-7995226401121364565
  72. J. P. YeZ. G. GaoJ. YinQ. HeHypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese miceThe American Journal of Physiology - Endocrinology and Metabolism20072934E1118E1E2810.1152/ajpendo.00435.20072-s2.0-3514885459917666485
  73. H. ThangarajahD. C. YaoE. I. ChangThe molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissuesProceedings of the National Academy of Sciences of the United States of America200910632135051351010.1073/pnas.09066701062-s2.0-6944910853619666581
  74. M. PasaricaO. R. SeredaL. M. RedmanReduced adipose tissue oxygenation in human obesity evidence for rarefaction, macrophage Chemotaxis, and inflammation without an angiogenic responseDiabetes200958371872510.2337/db08-10982-s2.0-6274916701019074987
  75. S. NielsenZ. GuoC. M. JohnsonD. D. HensrudM. D. JensenSplanchnic lipolysis in human obesityThe Journal of Clinical Investigation2004113111582158810.1172/JCI2104715173884
  76. Y. S. LeeJ. W. KimO. OsborneIncreased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesityCell201415761339135210.1016/j.cell.2014.05.0122-s2.0-8490207531824906151
  77. G. H. GoossensA. BizzarriN. VenteclefIncreased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammationCirculation20111241677610.1161/Circulationaha.111.0278132-s2.0-7996035985321670228
  78. S. CintiG. MitchellG. BarbatelliAdipocyte death defines macrophage localization and function in adipose tissue of obese mice and humansJournal of Lipid Research200546112347235510.1194/jlr.M500294-JLR2002-s2.0-2744443732116150820
  79. D. MazzattiF. L. LimA. O'HaraI. S. WoodP. TrayhurnA microarray analysis of the hypoxia-induced modulation of gene expression in human adipocytesArchives of Physiology and Biochemistry2012118311212010.3109/13813455.2012.6546112-s2.0-8486256620122352407
  80. S. BiswasR. MukherjeeN. TapryalA. K. SinghC. K. MukhopadhyayInsulin regulates hypoxia-inducible factor-1 alpha transcription by reactive oxygen species sensitive activation of Sp1 in 3T3-L1 preadipocytePloS One201384, article e62128ARTN e6212810.1371/journal.pone.00621282-s2.0-8487659295423626778
  81. I. R. BotusanV. G. SunkariO. SavuStabilization of HIF-1alpha is critical to improve wound healing in diabetic miceProceedings of the National Academy of Sciences of the United States of America200810549194261943110.1073/pnas.08052301052-s2.0-5804920972719057015
  82. H. ThangarajahI. N. VialR. H. GroganHIF-1alpha dysfunction in diabetesCell Cycle (Georgetown, Texas)201091757910.4161/cc.9.1.1037120016290
  83. S. ZhouS. LechpammerJ. S. GreenbergerJ. GlowackiHypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-beta/Smad3 signalingThe Journal of Biological Chemistry200528024226882269610.1074/jbc.M4129532002-s2.0-2074444994515845540
  84. K. H. KimM. J. SongJ. ChungH. ParkJ. B. KimHypoxia inhibits adipocyte differentiation in a HDAC-independent mannerBiochemical and Biophysical Research Communications200533341178118410.1016/j.bbrc.2005.06.0232-s2.0-2134444212715975549
  85. C. D. ByrneHypoxia and non-alcoholic fatty liver diseaseClinical Science2010118639740010.1042/CS200905652-s2.0-7314910906719900166
  86. S. FujisakaI. UsuiM. IkutaniAdipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1alpha-dependent and HIF-1alpha-independent manner in obese miceDiabetologia20135661403141210.1007/s00125-013-2885-12-s2.0-8487772549023494472
  87. G. L. SemenzaHydroxylation of HIF-1: Oxygen sensing at the molecular levelPhysiology200419417618210.1152/physiol.00001.200415304631
  88. S. H. KimD. HwangH. ParkE. G. YangH. S. ChungS. Y. KimThe action of HIF-3alpha variants on HIF-2alpha-HIF-1beta heterodimer formation is directly probed in live cellsExperimental Cell Research2015336232933710.1016/j.yexcr.2015.06.0172-s2.0-8493796773426160453
  89. Z. AranyL. E. HuangR. EcknerAn essential role for p300/CBP in the cellular response to hypoxiaProceedings of the National Academy of Sciences of the United States of America19969323129691297310.1073/pnas.93.23.129692-s2.0-002980355200298035528917528
  90. J. WanH. ChaiZ. YuHIF-1alpha effects on angiogenic potential in human small cell lung carcinomaJournal of Experimental & Clinical Cancer Research : CR201130p. 7710.1186/1756-9966-30-772-s2.0-8005160079421843314
  91. Q. KeM. CostaHypoxia-inducible factor-1 (HIF-1)Molecular Pharmacology20067051469148010.1124/mol.106.0270292-s2.0-3375116938716887934
  92. Y. V. LiuJ. H. BaekH. ZhangR. DiezR. N. ColeG. L. SemenzaRACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alphaMolecular Cell200725220721710.1016/j.molcel.2007.01.0012-s2.0-3384625499917244529
  93. T. HagenC. T. TaylorF. LamS. MoncadaRedistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alphaScience200330256521975197810.1126/science.10888052-s2.0-034813474114671307
  94. P. FraislCrosstalk between oxygen- and nitric oxide-dependent signaling pathways in angiogenesisExperimental Cell Research201331991331133910.1016/j.yexcr.2013.02.0102-s2.0-8487710255423485765
  95. G. F. BenderroX. Y. SunY. Z. KuangJ. C. LaMannaDecreased VEGF expression and microvascular density, but increased HIF-1 and 2 alpha accumulation and EPO expression in chronic moderate hyperoxia in the mouse brainBrain Research20121471465510.1016/j.brainres.2012.06.0552-s2.0-8486469986822820296
  96. A. LeihererK. GeigerA. MuendleinH. DrexelHypoxia induces a HIF-1alpha dependent signaling cascade to make a complex metabolic switch in SGBS-adipocytesMolecular and Cellular Endocrinology20143831-2213110.1016/j.mce.2013.11.0092-s2.0-8489110132924275182
  97. C. JiangA. QuT. MatsubaraDisruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed miceDiabetes201160102484249510.2337/db11-01742-s2.0-8005340865321873554
  98. X. ZhangK. S. LamH. YeAdipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in miceThe Journal of Biological Chemistry201028543328693287710.1074/jbc.M110.1355092-s2.0-7795850812120716529
  99. I. ShimizuT. AprahamianR. KikuchiVascular rarefaction mediates whitening of brown fat in obesityThe Journal of Clinical Investigation201412452099211210.1172/JCI716432-s2.0-8489975549124713652
  100. Y. XueN. PetrovicR. CaoHypoxia-independent angiogenesis in adipose tissues during cold acclimationCell Metabolism2009919910910.1016/j.cmet.2008.11.0092-s2.0-5784915391719117550
  101. C. RammosM. TotzeckR. DeenenDietary nitrate is a modifier of vascular gene expression in old male miceOxidative Medicine and Cellular Longevity20152015p. 1265826410.1155/2015/6582642-s2.0-8492577381825838870
  102. L. D. RobertsT. AshmoreA. O. KotwicaInorganic nitrate promotes the browning of white adipose tissue through the nitrate-nitrite-nitric oxide pathwayDiabetes201564247148410.2337/db14-04962-s2.0-8492192404425249574
  103. M. P. HezelM. LiuT. A. SchifferEffects of long-term dietary nitrate supplementation in miceRedox Biology2015523424210.1016/j.redox.2015.05.0042-s2.0-8493066449226068891
  104. R. D. RudicE. G. SheselyN. MaedaO. SmithiesS. S. SegalW. C. SessaDirect evidence for the importance of endothelium-derived nitric oxide in vascular remodelingThe Journal of Clinical Investigation1998101473173610.1172/JCI16999466966
  105. B. J. KrauseR. Del RioE. A. MoyaM. Marquez-GutierrezP. CasanelloR. IturriagaArginase-endothelial nitric oxide synthase imbalance contributes to endothelial dysfunction during chronic intermittent hypoxiaJournal of Hypertension201533351552410.1097/HJH.00000000000004532-s2.0-8492234370725629363
  106. J. O. LundbergE. WeitzbergM. T. GladwinThe nitrate-nitrite-nitric oxide pathway in physiology and therapeuticsNature Reviews Drug Discovery20087215616710.1038/nrd24662-s2.0-3884916273018167491
  107. N. S. BryanM. B. GrishamMethods to detect nitric oxide and its metabolites in biological samplesFree Radical Biology & Medicine200743564565710.1016/j.freeradbiomed.2007.04.0262-s2.0-3454709389017664129
  108. B. McNallyJ. L. GriffinL. D. RobertsDietary inorganic nitrate: From villain to hero in metabolic disease?Molecular Nutrition & Food Research2016601677810.1002/mnfr.2015001532-s2.0-849529892458495298924526227946
  109. S. DaunceyCan dietary nitrate supplements improve tolerance to hypoxia?Journal of the Intensive Care Society201213319820410.1177/175114371201300306
  110. A. GhasemiS. ZahediaslIs nitric oxide a hormone?Iranian Biomedical Journal2011153596521987110
  111. C. P. PrietoB. J. KrauseC. QuezadaR. San MartinL. SobreviaP. CasanelloHypoxia-reduced nitric oxide synthase activity is partially explained by higher arginase-2 activity and cellular redistribution in human umbilical vein endotheliumPlacenta2011321293294010.1016/j.placenta.2011.09.0032-s2.0-8485916188121962305
  112. X. GaoX. XuS. BelmadaniTNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injuryArteriosclerosis, Thrombosis, and Vascular Biology20072761269127510.1161/ATVBAHA.107.1425212-s2.0-342493194703424931947017413034
  113. M. SinghG. PadhyP. VatsK. BhargavaN. K. SethyHypobaric hypoxia induced arginase expression limits nitric oxide. availability and signaling in rodent heartBiochimica et Biophysica Acta-General Subjects2014184061817182410.1016/j.bbagen.2014.01.0152-s2.0-8489698359324440670
  114. J. PernowC. JungArginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?Cardiovascular Research201398333434310.1093/cvr/cvt0362-s2.0-848779510828487795108223417041
  115. H. WangA. X. WangK. AylorE. J. BarrettNitric oxide directly promotes vascular endothelial insulin transportDiabetes201362124030404210.2337/db13-062723863813
  116. M. A. PotenzaF. L. MarasciuloD. M. ChieppaInsulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 productionAmerican Journal of Physiology-Heart and Circulatory Physiology20052892H813HH2210.1152/ajpheart.00092.20052-s2.0-2374451166515792994
  117. J. A. KimM. MontagnaniK. K. KohM. J. QuonReciprocal relationships between insulin resistance and endothelial dysfunction - molecular and pathophysiological mechanismsCirculation2006113151888190410.1161/Circulationaha.105.5632132-s2.0-3364617895516618833
  118. B. SpiegelhalderG. EisenbrandR. PreussmannInfluence of dietary nitrate on nitrite content of human saliva: possible relevance to in vivo formation of N-nitroso compoundsFood and Cosmetics Toxicology197614654554810.1016/S0015-6264(76)80005-32-s2.0-001704643800170464381017769
  119. P. F. SwannCarcinogenic risk from nitrite, nitrate and N-nitrosamines in foodProceedings of the Royal Society of Medicine1977702113115859806
  120. A. S. PannalaA. R. ManiJ. P. SpencerThe effect of dietary nitrate on salivary, plasma, and urinary nitrate metabolism in humansFree Radical Biology & Medicine200334557658410.1016/S0891-5849(02)01353-92-s2.0-003737138712614846
  121. Y. TangH. JiangN. S. BryanNitrite and nitrate: cardiovascular risk-benefit and metabolic effectCurrent Opinion in Lipidology2011221111510.1097/MOL.0b013e328341942c2-s2.0-7875161537921102328
  122. T. NyströmH. OrtsäterZ. HuangInorganic nitrite stimulates pancreatic islet blood flow and insulin secretionFree Radical Biology & Medicine20125351017102310.1016/j.freeradbiomed.2012.06.0312-s2.0-8486481567322750508
  123. F. KimK. A. TysselingJ. RiceFree fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKβArteriosclerosis, Thrombosis, and Vascular Biology200525598999410.1161/01.ATV.0000160549.60980.a82-s2.0-209444367772094443677715731493
  124. L. JiaC. R. ViannaM. FukudaHepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistanceNature Communications20145p. 387810.1038/ncomms48782-s2.0-8490045723824815961
  125. T. YangM. PeleliC. ZollbrechtInorganic nitrite attenuates NADPH oxidase-derived superoxide generation in activated macrophages via a nitric oxide-dependent mechanismFree Radical Biology & Medicine20158315916610.1016/j.freeradbiomed.2015.02.0162-s2.0-8492667944025724690
  126. M. CarlstromA. E. PerssonE. LarssonDietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertensionCardiovascular Research2011893574585cvq366 [pii]10.1093/cvr/cvq3662-s2.0-7955149579821097806
  127. S. JeddiS. KhalifiM. GhanbariF. BageripourA. GhasemiEffects of nitrate intake on myocardial ischemia-reperfusion injury in diabetic ratsArquivos Brasileiros de Cardiologia2016107433934710.5935/abc.201601372-s2.0-8499462742727849257
  128. E. H. ChiuC. S. LiuT. Y. TanK. C. ChangVenturi mask adjuvant oxygen therapy in severe acute ischemic strokeArchives of Neurology200663574174410.1001/archneur.63.5.74116682544
  129. T. ToyamaR. SekiS. KasamaEffectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apneaCirculation Journal : Official Journal of the Japanese Circulation Society200973229930410.1253/circj.CJ-07-02972-s2.0-5944909994319122308
  130. M. H. BennettJ. FeldmeierR. SmeeC. MilrossHyperbaric oxygenation for tumour sensitisation to radiotherapyThe Cochrane Database of Systematic Reviews20124, article CD00500710.1002/14651858.CD005007.pub322513926
  131. Y. Feldman-IdovY. MelamedS. LinnL. OrePrognostic factors predicting ischemic wound healing following hyperbaric oxygenation therapyWound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society201321341842710.1111/wrr.120382-s2.0-8487758141423590699
  132. D. WilkinsonI. M. ChapmanL. K. HeilbronnHyperbaric oxygen therapy improves peripheral insulin sensitivity in humansDiabetic Medicine : A Journal of the British Diabetic Association201229898698910.1111/j.1464-5491.2012.03587.x2-s2.0-8486400499822269009
  133. H. KatoJ. ArakiK. DoiNormobaric hyperoxygenation enhances initial survival, regeneration, and final retention in fat graftingPlastic and Reconstructive Surgery2014134595195910.1097/PRS.00000000000006002-s2.0-8492502275325054244
  134. T. MatsunagaS. LiT. AdachiHyperoxia reverses glucotoxicity-induced inhibition of insulin secretion in rat INS-1 beta cellsBioscience, Biotechnology, and Biochemistry201478584385010.1080/09168451.2014.9051752-s2.0-8492352462925035988
  135. N. FujitaF. NagatomoS. MurakamiH. KondoA. IshiharaH. FujinoEffects of hyperbaric oxygen on metabolic capacity of the skeletal muscle in type 2 diabetic rats with obesityThe Scientific World Journal20122012p. 963797810.1100/2012/6379782-s2.0-8486375278022778702
  136. Z. ZhangX. BaiK. DuActivation of cholinergic anti-inflammatory pathway contributes to the protective effects of 100% oxygen inhalation on zymosan-induced generalized inflammation in miceThe Journal of Surgical Research20121742e75e8310.1016/j.jss.2011.10.0372-s2.0-8486278587822261596
  137. H. D. WilsonJ. R. WilsonP. N. FuchsHyperbaric oxygen treatment decreases inflammation and mechanical hypersensitivity in an animal model of inflammatory painBrain Research20061098112612810.1016/j.brainres.2006.04.0882-s2.0-3374777369716750177
  138. S. MilstienZ. KatusicOxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial functionBiochemical and Biophysical Research Communications1999263368168410.1006/bbrc.1999.14222-s2.0-003352741310512739
  139. S. R. ThomOxidative stress is fundamental to hyperbaric oxygen therapyJournal of Applied Physiology2009106398899510.1152/japplphysiol.91004.20082-s2.0-6434908422418845776
  140. A. MartiM. A. Martinez-GonzalezJ. A. MartinezInteraction between genes and lifestyle factors on obesityProceedings of the Nutrition Society20086711810.1017/S002966510800596x2-s2.0-3884909974518234126
  141. A. MisraL. KhuranaObesity and the metabolic syndrome in developing countriesThe Journal of Clinical Endocrinology and Metabolism20089311Supplement 1S93010.1210/jc.2008-15952-s2.0-5584913721218987276
  142. P. Gonzalez-MuniesaA. Lopez-PascualJ. de AndresImpact of intermittent hypoxia and exercise on blood pressure and metabolic features from obese subjects suffering sleep apnea-hypopnea syndromeJournal of Physiology and Biochemistry201571358959910.1007/s13105-015-0410-32-s2.0-8493946806725913417
  143. F. J. LipplS. NeubauerS. SchipferHypobaric hypoxia causes body weight reduction in obese subjectsObesity201018467568110.1038/oby.2009.5092-s2.0-7795018884120134417
  144. A. Lopez-PascualM. Bes-RastrolloC. Sayon-OreaLiving at a geographically higher elevation is associated with lower risk of metabolic syndrome: prospective analysis of the SUN cohortFrontiers in Physiology20177p. 658ARTN 65810.3389/fphys.2016.0065828101063
  145. B. OstadalF. KolarCardiac adaptation to chronic high-altitude hypoxia: Beneficial and adverse effectsRespiratory Physiology & Neurobiology20071582-322423610.1016/j.resp.2007.03.0052-s2.0-3454868459817442631
  146. P. QuinteroF. I. MilagroJ. CampionJ. A. MartinezImpact of oxygen availability on body weight managementMedical Hypotheses201074590190710.1016/j.mehy.2009.10.0222-s2.0-7795102227819913361
  147. C. T. TaylorB. D. KentS. J. CrinionW. T. McNicholasS. RyanHuman adipocytes are highly sensitive to intermittent hypoxia induced NF-kappaB activity and subsequent inflammatory gene expressionBiochemical and Biophysical Research Communications2014447466066510.1016/j.bbrc.2014.04.0622-s2.0-8490045131024755071
  148. M. LondahlP. KatzmanA. NilssonC. HammarlundHyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetesDiabetes Care2010335998100310.2337/dc09-17542-s2.0-7795491540120427683
  149. P. Tahep ldG. ValenJ. StarkopfC. KairaneM. ZilmerJ. VaagePretreating rats with hyperoxia attenuates ischemia-reperfusion injury of the heartLife Sciences200168141629164010.1016/S0024-3205(01)00964-X2-s2.0-0035936722003593672211263675
  150. H. FarquharM. WeatherallM. WijesingheSystematic review of studies of the effect of hyperoxia on coronary blood flowAmerican Heart Journal2009158337137710.1016/j.ahj.2009.05.0372-s2.0-6884909178519699859
  151. E. A. ResseguieR. J. StaverskyP. S. BrookesM. A. O'ReillyHyperoxia activates ATM independent from mitochondrial ROS and dysfunctionRedox Biology2015517618510.1016/j.redox.2015.04.0122-s2.0-8493094576825967673
  152. M. EntezariM. JavdanD. J. AntoineInhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injuryRedox Biology2014231432210.1016/j.redox.2014.01.0132-s2.0-8489382473524563849
  153. Y. KandaT. HinataS. W. KangY. WatanabeReactive oxygen species mediate adipocyte differentiation in mesenchymal stem cellsLife Sciences2011897-825025810.1016/j.lfs.2011.06.0072-s2.0-7996101190121722651
  154. Y. XiongM. LeiS. FuY. FuEffect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetesLife Sciences200577214915910.1016/j.lfs.2004.10.0622-s2.0-1804437795715862600
  155. M. CarlstromF. J. LarsenT. NystromDietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient miceProceedings of the National Academy of Sciences of the United States of America201010741177161772010.1073/pnas.10088721072-s2.0-7804923830820876122
  156. G. H. GoossensE. E. BlaakAdipose tissue dysfunction and impaired metabolic health in human obesity: A matter of oxygen?Frontiers in Endocrinology20156p. 5510.3389/fendo.2015.000552-s2.0-8493065952225964776
  157. L. LandiniM. J. HonkaE. FerranniniP. NuutilaAdipose tissue oxygenation in obesity: a matter of cardiovascular risk?Current Pharmaceutical Design2015221687610.2174/138161282266615110911195826556270
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as obesity.